Hadasit Health Innovation
Creating synergies between academia, industry, and medicine

Assessment of relative quantitative effect of somatic point mutations at the individual tumor level for prioritization

Our Solution

Computational model to assess the relative strength of every point mutation is 535 (now expanded to >700) cancer genes.

  • This is a continuous quantitative model
  • This model is available for 535 cancer genes but only for variants that occurred

Applications

  • Germline variants: genetic consultation for carrier of mutations. The model has potential to assess relative risk
  • Somatic variants: Identification of mutations to target for precision medicine in cancer. The  model can prioritize genetic profile of each tumor for drug targeting

IP

Priority application filed

Contact
Hadasit

Jerusalem BioPark, Hadassah Ein Kerem POB 12000, Jerusalem 91120, Israel
Tel. +972-2-6778757 Fax. +972-2-6437712 Email. infohadasit@hadassah.org.il